MarketMindUS Markets Closed
AI-assisted · Not financial adviceNot adviceAI-assisted · Not financial advice.
Optimism for HIMS grows amid FDA news, while concerns linger over subscriber growth. Investors should weigh potential against market realities.
Hims & Hers Health sees stock surge after target raise
Target: $30 avg (-2% upside)
7 Buy · 13 Hold · 0 Sell
Based on curated news sources (not retail comments)
Over the last 7 days: While the price target increase suggests strong potential, the recent decline in stock price poses a concern.